Close

PTC Therapeutics (PTCT) Receives EMA CHMP Approval for Translarna Marketing Authorization in mmDMD

Go back to PTC Therapeutics (PTCT) Receives EMA CHMP Approval for Translarna Marketing Authorization in mmDMD

Credit Suisse Upgrades PTC Therapeutics (PTCT) to Outperform; ROW Translarna Sales Risk Off the Table

November 14, 2016 6:18 AM EST

Credit Suisse upgraded PTC Therapeutics (NASDAQ: PTCT) from Neutral to Outperform with a price target of $25.00 (from $15.00), saying they believe much of the near-term risk associated with ROW Translarna sales are off the table.

Analyst Alethia Young commented, "PTC announced this morning that CHMP is... More

PTC Therapeutics' (PTCT) Price Target Raised to $13 at RBC Capital

November 11, 2016 12:57 PM EST

RBC Capital maintained a Sector Perform rating on PTC Therapeutics (NASDAQ: PTCT) and raised its price target to $13.00 (from $5.00). Earlier CHMP recommended the renewal of the conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients five years and older.

Commenting on developments, Simos Simeonidis said, "We had assigned a 50% chance that Translarna would be pulled, given its failure on the... More

PTC Therapeutics (PTCT) Surges After CHMP Recommends Renewal of Translarna Marketing Authorization

November 11, 2016 7:24 AM EST

PTC Therapeutics (NASDAQ: PTCT) surges 82% in pre-open trade after the company announced that the Committee for Medicinal... More

PTC Therapeutics' (PTCT) Translarna Receives EMA Conditional Marketing Renewal

November 11, 2016 7:14 AM EST

The CHMP completed its scientific assessment of the annual renewal of the conditional marketing authorisation for Translarna (ataluren) and recommended that the conditional marketing authorisation be renewed.

As part of the CHMP assessment, the Committee reviewed all available data, including the results of a study performed by the marketing authorisation holder as a requirement of the conditional marketing authorisation after initial approval. Although the data available to date continue to indicate that Translarna slows the progression of the disease and there are no major safety... More